Aura Biosciences
Aura Biosciences Inc is an American clinical-stage biotechnology company focused on developing a novel class of virus-like drug conjugate (VDC) therapies designed to target and destroy cancer cells selectively while preserving surrounding healthy tissue, prominently featuring treatments for ocular oncology and rare cancers. The company utilizes its proprietary VDC technology platform to create targeted oncology treatments, including its lead candidate bel-zuMT for choroidal melanoma and other solid tumors. Its core business activities encompass preclinical and clinical biopharmaceutical research, targeted oncology drug design, clinical trial execution, and regulatory compliance. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its drug research pipeline through public equity offerings and pharmaceutical collaborations. Aura Biosciences holds a pioneering position in targeted oncology and virus-like drug conjugate therapeutics. The company is headquartered in Boston, Massachusetts, United States, and its common stock trades on the Nasdaq Global Select Market.
2 of the funds FundTelligence covers report a position in Aura Biosciences.
- Legal name
- Aura Biosciences Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Aura Biosciences
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.39 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.04 % (full portfolio disclosed, October 2026)